In the course of our screening program to discover antimalarial antibiotics from soil microorganisms which are active against drug-resistant parasites in vitro and in vivo, we previously reported that the polyether antibiotics X-206 and K-41 and other microbial metabolites exhibited potent antimalarial properties1-3). Thereafter, we found that a substance produced by an actinomycete strain OM-0060 had potent and selective antimalarial activities in vitro and in vivo. It was identified as borrelidin, a known nonglycosidic 18-membered macrolide antibiotic with a cyclopentanecarboxylic acid side chain ( Fig. 1)4 ,5). We report here the antimalarial profile of borrelidin in comparison with those of clinically used antimalarial drugs.
Borrelidin was isolated from the cultured broth of an actinomycete strain OM-0060. In vitro activities against Plasmodium falciparum strains K1 (drug-resistant) and FCR3 (drug-sensitive), and cytotoxicity against human diploid embryonic cell line MRC-5 were measured as described previously1). Rodent malaria-derived strains for in vivo 4-days suppressive testing, P. berghei N (drugsensitive) and P. yoelii ssp. NS (chloroquine-resistant) were used to assess in vivo antimalarial activities as described previously1,2). Test compounds were dissolved in 10% DMSO-Tween 80 aqueous solution and administered subcutaneously (s.c.) or orally (p.o.) to the mice two hours after infection with parasites (Day 0). Then the compounds were successively administered (s.c. or p.o.) to the infected mice once a day for 3 days (Days 1-3). On the day after the last treatment (Day 4), thin blood films were made from the tail blood of the mice, and the parasitaemia was determined as described previously2). Table 1 shows the in vitro antimalarial activities of borrelidin and the standard antimalarial drugs. Borrelidin showed more potent activity against the drug-resistant K1 strain of P. falciparum than the clinically used antimalarials, artemether, artesunate and chloroquine. Furthermore, borrelidin showed similar activity against the drug-sensitive FCR3 strain of P. falciparum to artemether and artesunate, and was more potent than chloroquine. The cytotoxicity of borrelidin against MRC-5 cells was relatively low (the IC50 value: 410nM). Borrelidin showed high selectivity indexes with the ratios of 216 and 228 for the MRC-5 cells/K1 strain and MRC-5 cells/FCR3 strain, respectively. Table 2 shows a preliminary comparison of the in vivo subcutaneous antimalarial activities of borrelidin and the standard antimalarial drugs. Borrelidin had antimalarial activity against both rodent malaria-derived P. berghei N and P. yoelii ssp. NS. Especially, borrelidin showed more potent subcutaneous antimalarial effects than artemether, artesunate and chloroquine against the chloroquine resistant strain (P. yoelii ssp. NS). The ED50 and ED90 values of borrelidin against P. yoelii ssp. NS were lower by factors 5.7-64 and 6.4->125, respectively, than those of the other three drugs. Borrelidin also showed more potent antimalarial effects than artemether, artesunate and chloroquine when the drugs were administered orally (Table 3 ). The ED50 and ED90 values of borrelidin were lower by factors 13-17 and 36->91, respectively, than those of the other three drugs.
It is known that borrelidin has inhibitory activities against Borrelia4), Treponema6,7), viruses8), certain micrococci9), tumor cells10), angiogenesis11) and a yeast cyclin-dependent kinase12), and that its mode of antibiotic action in sensitive microorganisms involves selective inhibition of threonyl-tRNA synthetase13). WAKABAYASHI et al. reported that it inhibits both threonyl-tRNA synthetase and protein synthesis in cultured rat cells11). However, the finding of the antimalarial activity of borrelidin is novel and the above data are the first report of such properties. SCHNITZER et al.14) and SINGH et al.6) reported that the LD50 values (i.v., s.c. and p.o. in mice) of borrelidin were 39.0, 74.7 and slightly less than 400mg/kg, respectively. We also determined that the acute subcutaneous toxicity of borrelidin (the LD50 value in mice) was >50mg/kg. However, we did observe toxicity (loss of weight, mortality) when the compound was delivered by the p.o. route (preliminary results suggest an LD50 of 16.4mg/kg). These effects are being investigated further.
The above results reveal that borrelidin is a promising lead compound for a new type of the antimalarial drug. 
